Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Real Time Quote from BATS)

$14.49 USD

14.49
1,172,390

-0.24 (-1.63%)

Updated Oct 8, 2024 03:55 PM ET

After-Market: $14.46 -0.03 (-0.21%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche (RHHBY) Receives FDA Approval For Cobas Zika Test

by Zacks Equity Research

The approval of cobas Zika will expands Roche's industry-leading donor screening portfolio for blood-borne diseases.

    ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status

    by Zacks Equity Research

    ACADIA Pharmaceuticals' (ACAD) Nuplazid granted Breakthrough Therapy Designation for dementia-related psychosis. A phase III study for the same was also initiated.

      Ligand (LGND) Signs Deal to Acquire Crystal Bioscience

      by Zacks Equity Research

      Ligand (LGND) inked a deal to acquire Crystal Bioscience, a leader in chicken-derived fully-human antibody generation, for $25 million in cash.

        Celsion's Immunotherapy Candidate Impresses, Stock Surges

        by Zacks Equity Research

        Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.

          Emergent Completes Acquisition of Anthrax Drug Raxibacumab

          by Zacks Equity Research

          Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.

            Allergan Authorizes New $2B Share Buyback Plan, Stock Up

            by Zacks Equity Research

            Allergan plc (AZN) sanctions a new stock repurchase program. The company also reiterates its commitment toward annual hike of quarterly cash dividend.

              Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III

              by Zacks Equity Research

              GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.

                Supernus Drops SPN-810's Lower Dose Test in Phase III Trials

                by Zacks Equity Research

                Supernus (SUPN) decides to stop evaluating the lower dose option of SPN-810 for treatment of impulsive aggression. However, the company will carry on with the study of higher dose arm or placebo.

                  Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD

                  by Zacks Equity Research

                  The FDA approves GlaxoSmithKline (GSK) and Innoviva's triple combination therapy, FF/UMEC/VI, for COPD. The drug will be accessed as Trelegy Ellipta in the U.S. market.

                    BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA

                    by Zacks Equity Research

                    The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.

                      GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down

                      by Zacks Equity Research

                      GTx (GTXI) posts positive data from a phase II study of enobosarm for treating women with stress urinary incontinence. However, shares dip possibly with the release falling below market estimates.

                        Alexion (ALXN) Reports Interim Results for Soliris Study

                        by Zacks Equity Research

                        Alexion (ALXN) announced results from an interim analysis of an ongoing phase III REGAIN study of Soliris. The study showed sustained treatment benefits of Soliris treatment for patients with refractory generalized myasthenia gravis.

                          Perrigo's Stock Up, Starboard's CEO Calls it a Key Pick

                          by Zacks Equity Research

                          Perrigo's (PRGO) shares rise with Jeff Smith, CEO of Starboard Value, certifying the company as a top investment pick, courtesy its highly potential generic business.

                            Marinus Stock Surges on Successful Phase II Epilepsy Study

                            by Zacks Equity Research

                            Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.

                              Ultragenyx's Burosumab Positive in Phase II for XLH and TIO

                              by Zacks Equity Research

                              Ultragenyx's (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.

                                BioMarin Presents Interim Data on BMN 250 from Phase I/II

                                by Zacks Equity Research

                                BioMarin's (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.

                                  Merck (MRK) Opts for Buying German Immuno-Oncology Biotech

                                  by Zacks Equity Research

                                  Merck (MRK) to acquire Germany-based Rigontec, a leader in retinoic acid-inducible gene I (RIG-I), a novel immuno-oncology treatment approach targeting therapeutics.

                                    The Medicines Company's Infection Drug Vabomere Gets FDA Nod

                                    by Zacks Equity Research

                                    The Medicines Company's (MDCO) infection-resistant antibiotic Vabomere secures a fast FDA approval for urinary tract diseases. The drug is likely to hit the market in fourth-quarter 2017.

                                      FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down

                                      by Zacks Equity Research

                                      Acorda (ACOR) receives a refusal to file (RTF) letter from the FDA in connection with Inbrija's NDA.

                                        The Medicines Co's Inclisiran Positive in Extension Study

                                        by Zacks Equity Research

                                        The Medicines Company (MDCO) and partner Alnylam publish new one-year safety and efficacy data from phase II extension study of Inclisiran for hypercholesterolemia.

                                          Anthera's Blisibimod Positive in Phase II Extension Study

                                          by Zacks Equity Research

                                          Anthera's (ANTH) blisibimod passes test in an extended phase II study to prove efficacy for IgA nephropathy treatment. The study also shows a trend toward preservation of renal function.

                                            J&J's (JNJ) Xarelto/Aspirin Regimen Positive in Phase III

                                            by Zacks Equity Research

                                            J&J's (JNJ) blood thinner Xarelto shows a significant risk reduction in major cardiovascular events in patients with stable coronary and peripheral artery disease.

                                              Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval

                                              by Zacks Equity Research

                                              The EU approves of Minerva's (NERV) amendment of MIN-202 license agreement with Janssen. Per the deal, Minerva will receive an upfront payment from Janssen.

                                                Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars

                                                by Zacks Equity Research

                                                Adamas Pharmaceuticals' (ADMS) Gocovri was approved by the FDA for treating dyskinesia in patients with Parkinson's disease. This led to an upside in shares.

                                                  Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate

                                                  by Zacks Equity Research

                                                  Ultragenyx (RARE) forwards a BLA to the FDA for burosumab with a view to treat patients with X-linked hypophosphatemia (XLH). The decision on acceptance will be known within a couple of months.